Primary partial response with tenofovir monotherapy: two adults and one child

Introduction: Three treatment-naïve cases with chronic hepatitis B (CHB) were reported in terms of a partial response to tenofovir disoproxil (TDF) monotherapy and antiviral-drug resistance. Methodology: In this retrospective, case series study, patients who were treated for CHB at the departmen...

Full description

Saved in:
Bibliographic Details
Main Author: Habip Gedik
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2022-05-01
Series:Journal of Infection in Developing Countries
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/12054
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850035925818540032
author Habip Gedik
author_facet Habip Gedik
author_sort Habip Gedik
collection DOAJ
description Introduction: Three treatment-naïve cases with chronic hepatitis B (CHB) were reported in terms of a partial response to tenofovir disoproxil (TDF) monotherapy and antiviral-drug resistance. Methodology: In this retrospective, case series study, patients who were treated for CHB at the departments of infectious diseases and clinical microbiology, University of Medical Science Bakırköy Dr. Sadi Konuk Training and Research Hospital were evaluated. Results: A 26-year-old female patient and a 59-year-old male patient achieved sustained viral response with TDF (245 mg) or tenofovir alafenamide (TAF, 25 mg) + entekavir (ETV, 1 mg) combination therapy after failure with TDF monotherapy. The son of the female patient who was diagnosed with CHB infection due to a probable mother-to-child transmission did not achieve a complete viral response with interferon alfa-2b therapy for three months followed by lamivudine therapy for 19 months. Conclusions: A TDF (245 mg) or TAF (25 mg) + ETV (1 mg) combination therapy is effective in the treatment of naïve patients with a partial response to the TDF monotherapy. A combination therapy including tenofovir and entecavir should be initiated to mothers with a primary partial response to the tenofovir monotherapy after the initial 32 weeks of pregnancy, as CHB may cause cirrhosis in the children due to a persistent inflammation in the liver subsequent to a vertical transmission.
format Article
id doaj-art-6dcb87cca8784e04bdc94a6d5c62b047
institution DOAJ
issn 1972-2680
language English
publishDate 2022-05-01
publisher The Journal of Infection in Developing Countries
record_format Article
series Journal of Infection in Developing Countries
spelling doaj-art-6dcb87cca8784e04bdc94a6d5c62b0472025-08-20T02:57:21ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802022-05-01160510.3855/jidc.12054Primary partial response with tenofovir monotherapy: two adults and one childHabip Gedik0Department of Infectious Diseases and Clinical Microbiology, Ministry of Health, Istanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey Introduction: Three treatment-naïve cases with chronic hepatitis B (CHB) were reported in terms of a partial response to tenofovir disoproxil (TDF) monotherapy and antiviral-drug resistance. Methodology: In this retrospective, case series study, patients who were treated for CHB at the departments of infectious diseases and clinical microbiology, University of Medical Science Bakırköy Dr. Sadi Konuk Training and Research Hospital were evaluated. Results: A 26-year-old female patient and a 59-year-old male patient achieved sustained viral response with TDF (245 mg) or tenofovir alafenamide (TAF, 25 mg) + entekavir (ETV, 1 mg) combination therapy after failure with TDF monotherapy. The son of the female patient who was diagnosed with CHB infection due to a probable mother-to-child transmission did not achieve a complete viral response with interferon alfa-2b therapy for three months followed by lamivudine therapy for 19 months. Conclusions: A TDF (245 mg) or TAF (25 mg) + ETV (1 mg) combination therapy is effective in the treatment of naïve patients with a partial response to the TDF monotherapy. A combination therapy including tenofovir and entecavir should be initiated to mothers with a primary partial response to the tenofovir monotherapy after the initial 32 weeks of pregnancy, as CHB may cause cirrhosis in the children due to a persistent inflammation in the liver subsequent to a vertical transmission. https://jidc.org/index.php/journal/article/view/12054HBVtenofovirresponseentecavircombinationtherapy
spellingShingle Habip Gedik
Primary partial response with tenofovir monotherapy: two adults and one child
Journal of Infection in Developing Countries
HBV
tenofovir
response
entecavir
combination
therapy
title Primary partial response with tenofovir monotherapy: two adults and one child
title_full Primary partial response with tenofovir monotherapy: two adults and one child
title_fullStr Primary partial response with tenofovir monotherapy: two adults and one child
title_full_unstemmed Primary partial response with tenofovir monotherapy: two adults and one child
title_short Primary partial response with tenofovir monotherapy: two adults and one child
title_sort primary partial response with tenofovir monotherapy two adults and one child
topic HBV
tenofovir
response
entecavir
combination
therapy
url https://jidc.org/index.php/journal/article/view/12054
work_keys_str_mv AT habipgedik primarypartialresponsewithtenofovirmonotherapytwoadultsandonechild